Virus against virus:strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer

• 作者: Momeneh Ghanaat Nasser Hashemi Goradel Arash Arashkia Nasim Ebrahimi Sajjad Ghorghanlu Ziba Veisi Malekshahi Esmail Fattahi Babak Negahdari Hami Kaboosi
• 来源期刊: 中国药理学报（英文版）
• 年，卷（期）: 2021,（12）
• 所属期刊栏目: Review Article
• 页码范围: 1981-1990
• 页数: 10页
• 语种: 英文

摘要

Although most human papillomavirus (HPV) infections are harmless,persistent infection with high-risk types of HPV is known to be the leading cause of cervical cancer.Following the infection of the epithelium and integration into the host genome,the oncogenic proteins E6 and E7 disrupt cell cycle control by inducing p53 and retinoblastoma (Rb) degradation.Despite the FDA approval of prophylactic vaccines,there are still issues with cervical cancer treatment;thus,many therapeutic approaches have been developed to date.Due to strong immunogenicity,a high capacity for packaging foreign DNA,safety,and the ability to infect a myriad of cells,adenoviruses have drawn attention of researchers.Adenovirus vectors have been used for different purposes,including as oncolytic agents to kill cancer cells,carrier for RNA interference to block oncoproteins expression,vaccines for eliciting immune responses,especially in cytotoxic T lymphocytes (CTLs),and gene therapy vehicles for restoring p53 and Rb function.